Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Ginekologia Polska
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

open access

Vol 94, No 9 (2023)
Research paper
Published online: 2022-10-20
View PDF Download PDF file View HTML
Get Citation

Increased risk of low infant birth weight in pregnant women with low PAPP-A values measured in the first trimester

Jozef Krawczyk1, Piotr Ratajczak2, Stefan Sajdak1
DOI: 10.5603/GP.a2022.0118
·
Ginekol Pol 2023;94(9):714-720.
Affiliations
  1. Division of Gynecological Surgery, Poznan University of Medical Sciences, Poznan, Poland
  2. Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Scienceses, Poznan, Poland, Poland

open access

Vol 94, No 9 (2023)
ORIGINAL PAPERS Obstetrics
Published online: 2022-10-20

Abstract

Objectives: Testing pregnant women as early as in the first trimester has multiple advantages. Firstly, the first trimester screening combining ultrasound and serum marker testing (PAPP-A and free β-hCG) offers the highest currently possible — except for expensive tests using cell-free DNA biomarkers from the mother’s blood (ccf DNA) — detectability of aneuploid fetuses. Secondly, nuchal translucency (NT) measurement helps determine the risk of numerous abnormalities other than aneuoploidies. Lastly, nearly complete ultrasound assessment of fetal anatomy can be performed as early as in the first trimester of pregnancy.

Material and methods: This study is based on prospective analysis. Study subjects were 236 pregnant women. One hundred thirty-one patients with a single pregnancy were qualified into the study group and had a combined ultrasound and biochemical screening for Down’s syndrome performed between 11 + 0 and 13 + 6 weeks of gestation, with the measured PAPP-A value at ≤ 0.50 MoM (multiples of the median). The control group comprised 105 pregnant women with PAPP-A value at a similar stage of pregnancy at > 0.5 MoM.

Results: The average observed value of the PAPP-A in the study group was 0.35 MoM while in the control group 1.29 MoM. Moreover, combined observation of infant birth weights in both groups compared to the PAPP-A MoM values has shown a significant relationship between those characteristics (r = 0.15, p = 0.0184).

Conclusions: The results showed that pregnant women with low PAPP-A MoM value measured during the first trimester have a higher risk of giving birth to a low-birth-weight infant (which is the value below 2500 g), than the pregnant women whose PAPP-A MoM value in the first trimester did not meet this criterion.

Abstract

Objectives: Testing pregnant women as early as in the first trimester has multiple advantages. Firstly, the first trimester screening combining ultrasound and serum marker testing (PAPP-A and free β-hCG) offers the highest currently possible — except for expensive tests using cell-free DNA biomarkers from the mother’s blood (ccf DNA) — detectability of aneuploid fetuses. Secondly, nuchal translucency (NT) measurement helps determine the risk of numerous abnormalities other than aneuoploidies. Lastly, nearly complete ultrasound assessment of fetal anatomy can be performed as early as in the first trimester of pregnancy.

Material and methods: This study is based on prospective analysis. Study subjects were 236 pregnant women. One hundred thirty-one patients with a single pregnancy were qualified into the study group and had a combined ultrasound and biochemical screening for Down’s syndrome performed between 11 + 0 and 13 + 6 weeks of gestation, with the measured PAPP-A value at ≤ 0.50 MoM (multiples of the median). The control group comprised 105 pregnant women with PAPP-A value at a similar stage of pregnancy at > 0.5 MoM.

Results: The average observed value of the PAPP-A in the study group was 0.35 MoM while in the control group 1.29 MoM. Moreover, combined observation of infant birth weights in both groups compared to the PAPP-A MoM values has shown a significant relationship between those characteristics (r = 0.15, p = 0.0184).

Conclusions: The results showed that pregnant women with low PAPP-A MoM value measured during the first trimester have a higher risk of giving birth to a low-birth-weight infant (which is the value below 2500 g), than the pregnant women whose PAPP-A MoM value in the first trimester did not meet this criterion.

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

small-for-gestational-age infants; PAPP-A protein; β-hCG; ultrasound scan

About this article
Title

Increased risk of low infant birth weight in pregnant women with low PAPP-A values measured in the first trimester

Journal

Ginekologia Polska

Issue

Vol 94, No 9 (2023)

Article type

Research paper

Pages

714-720

Published online

2022-10-20

Page views

430

Article views/downloads

821

DOI

10.5603/GP.a2022.0118

Bibliographic record

Ginekol Pol 2023;94(9):714-720.

Keywords

small-for-gestational-age infants
PAPP-A protein
β-hCG
ultrasound scan

Authors

Jozef Krawczyk
Piotr Ratajczak
Stefan Sajdak

References (40)
  1. Ciobanu A, Formuso C, Syngelaki A, et al. Prediction of small-for-gestational-age neonates at 35-37 weeks' gestation: contribution of maternal factors and growth velocity between 20 and 36 weeks. Ultrasound Obstet Gynecol. 2019; 53(4): 488–495.
    CrossRefPubMed
  2. Sonek J, Nicolaides K. Additional first-trimester ultrasound markers. Clin Lab Med. 2010; 30(3): 573–592.
    CrossRefPubMed
  3. Souka AP, Von Kaisenberg CS, Hyett JA, et al. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol. 2005; 192(4): 1005–1021.
    CrossRefPubMed
  4. Czuba B, Borowski D, Węgrzyn P, et al. Influence of first trimester biochemistry methodology on detection rate in screening for trisomy 21. Ginekol Pol. 2017; 88(9): 492–496.
    CrossRefPubMed
  5. Lin TM, Galbert SP, Kiefer D, et al. Characterization of four human pregnancy-associated plasma proteins. Am J Obstet Gynecol. 1974; 118(2): 223–236.
    CrossRefPubMed
  6. Spencer K, Ong C, Skentou H, et al. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn. 2000; 20(5): 411–416.
    PubMed
  7. Ziolkowska K, Dydowicz P, Sobkowski M, et al. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy. Ginekol Pol. 2019; 90(3): 161–166.
    CrossRefPubMed
  8. Bonno M, Oxvig C, Kephart GM, et al. Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta. Lab Invest. 1994; 71(4): 560–566.
    PubMed
  9. Clemmons DR, Busby W, Clarke JB, et al. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev. 1997; 8(1): 45–62.
    CrossRefPubMed
  10. Conover CA, Bale LK, Overgaard MT, et al. Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development. 2004; 131(5): 1187–1194.
    CrossRefPubMed
  11. Bischof P, DuBerg S, Herrmann W, et al. Pregnancy-associated plasma protein-A (PAPP-A) and hCG in early pregnancy. Br J Obstet Gynaecol. 1981; 88(10): 973–975.
    CrossRefPubMed
  12. Bischof P, Amandruz M, Weil-Franck C, et al. The disappearance rate of pregnancy-associated plasma protein-A (PAPP-A) after the end of normal and abnormal pregnancies. Arch Gynecol. 1984; 236(2): 93–98.
    CrossRefPubMed
  13. Kirkegaard I, Uldbjerg N, Oxvig C. Biology of pregnancy-associated plasma protein-A in relation to prenatal diagnostics: an overview. Acta Obstet Gynecol Scand. 2010; 89(9): 1118–1125.
    CrossRefPubMed
  14. Chang TC, Robson SC, Boys RJ, et al. Prediction of the small for gestational age infant: which ultrasonic measurement is best? Obstet Gynecol. 1992; 80(6): 1030–1038.
    PubMed
  15. Alberry M, Soothill P. Management of fetal growth restriction. Arch Dis Child Fetal Neonatal Ed. 2007; 92(1): F62–F67.
    CrossRefPubMed
  16. Robson SC, Chang TC. Intrauterine growth retardation. In: Reed G, Claireaux AC, Cockburn F. ed. Diseases of the Fetus and the Newborn. 2nd ed. Chapman and Hall, London 1994: 277–286.
  17. Owen P, Donnet ML, Ogston SA, et al. Standards for ultrasound fetal growth velocity. Br J Obstet Gynaecol. 1996; 103(1): 60–69.
    CrossRefPubMed
  18. Sovio U, White IR, Dacey A, et al. Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (POP) study: a prospective cohort study. Lancet. 2015; 386(10008): 2089–2097.
    CrossRefPubMed
  19. Hammami A, Mazer Zumaeta A, Syngelaki A, et al. Ultrasonographic estimation of fetal weight: development of new model and assessment of performance of previous models. Ultrasound Obstet Gynecol. 2018; 52(1): 35–43.
    CrossRefPubMed
  20. Hadlock FP, Harrist RB, Sharman RS, et al. Estimation of fetal weight with the use of head, body, and femur measurements--a prospective study. Am J Obstet Gynecol. 1985; 151(3): 333–337.
    CrossRefPubMed
  21. Ropacka-Lesiak M, Breborowicz G. [Management of pregnancy complicated by intrauterine fetal growth restriction]. Ginekol Pol. 2012; 83(5): 373–376.
    PubMed
  22. Spencer K, Crossley JA, Aitken DA, et al. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem. 2002; 39(Pt 6): 567–576.
    CrossRefPubMed
  23. Karim JN, Sau A. Low pregnancy associated plasma protein-A in the 1st trimester: is it a predictor of poor perinatal outcome? J Obstet Gynaecol. 2013; 33(4): 351–354.
    CrossRefPubMed
  24. Westergaard JG, Teisner B, Hau J, et al. Placental protein measurements in complicated pregnancies. I. Intrauterine growth retardation. Br J Obstet Gynaecol. 1984; 91(12): 1216–1223.
    CrossRefPubMed
  25. Pledger DR, Belfield A, Calder AA, et al. The predictive value of three pregnancy-associated proteins in the detection of the light-for-dates baby. Br J Obstet Gynaecol. 1984; 91(9): 870–874.
    CrossRefPubMed
  26. Salvig JD, Kirkegaard I, Winding TN, et al. Low PAPP-A in the first trimester is associated with reduced fetal growth rate prior to gestational week 20. Prenat Diagn. 2010; 30(6): 503–508.
    CrossRefPubMed
  27. Fox NS, Shalom D, Chasen ST. Second-trimester fetal growth as a predictor of poor obstetric and neonatal outcome in patients with low first-trimester serum pregnancy-associated plasma protein-A and a euploid fetus. Ultrasound Obstet Gynecol. 2009; 33(1): 34–38.
    CrossRefPubMed
  28. Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn. 2008; 28(1): 7–10.
    CrossRefPubMed
  29. Ziolkowska K, Tobola-Wrobel K, Dydowicz P, et al. The significance of maternal blood pregnancy-associated plasma protein A (PAPP-A) and free beta-subunit of human chorionic gonadotropin (β-hCG) levels for the risk assessment of fetal trisomy 18 during the first prenatal testing between 11 and 13+6 weeks of pregnancy. Ginekol Pol. 2020; 91(12): 748–754.
    CrossRefPubMed
  30. Scott F, Coates A, McLennan A. Pregnancy outcome in the setting of extremely low first trimester PAPP-A levels. Aust N Z J Obstet Gynaecol. 2009; 49(3): 258–262.
    CrossRefPubMed
  31. Smith GCS, Stenhouse EJ, Crossley JA, et al. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002; 87(4): 1762–1767.
    CrossRefPubMed
  32. Krantz D, Goetzl L, Simpson JL, et al. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol. 2004; 191(4): 1452–1458.
    CrossRefPubMed
  33. Peterson SE, Simhan HN. First-trimester pregnancy-associated plasma protein A and subsequent abnormalities of fetal growth. Am J Obstet Gynecol. 2008; 198(5): e43–e45.
    CrossRefPubMed
  34. Canini S, Prefumo F, Pastorino D, et al. Association between birth weight and first-trimester free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Fertil Steril. 2008; 89(1): 174–178.
    CrossRefPubMed
  35. Barrett SL, Bower C, Hadlow NC. Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes. Prenat Diagn. 2008; 28(1): 28–35.
    CrossRefPubMed
  36. Kabili G, Stricker R, Stricker R, et al. First trimester screening for trisomy 21; Do the parameters used detect more pathologies than just Down syndrome? Eur J Obstet Gynecol Reprod Biol. 2004; 114(1): 35–38.
    CrossRefPubMed
  37. Lawrence JB, Oxvig C, Overgaard MT, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A. 1999; 96(6): 3149–3153.
    CrossRefPubMed
  38. Laursen LS, Overgaard MT, Søe R, et al. Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett. 2001; 504(1-2): 36–40.
    CrossRefPubMed
  39. Kramer MS. Intrauterine growth and gestational duration determinants. Pediatrics. 1987; 80(4): 502–511.
    PubMed
  40. Spencer K, Bindra R, Cacho AM, et al. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Prenat Diagn. 2004; 24(3): 169–173.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl